Company Overview and News

 
Trading Halt

2017-06-19 londonstockexchange
In accordance with ASX Listing Rule 17.1 Oilex Ltd (ASX: OEX, AIM: OEX) hereby requests an immediate trading halt on the Company's securities from the commencement of trading Monday 19 June 2017.

 
Oilex granted an ASX trading halt

2017-06-19 proactiveinvestors.com.au
Oilex (ASX:OEX) has been granted a trading halt by the ASX, pending details in relation to the joint venture cash calls owing by its joint venture partner.

 
Trading Halt

2017-03-13 londonstockexchange
In accordance with ASX Listing Rule 17.1 Oilex Ltd (ASX: OEX, AIM: OEX) hereby requests an immediate trading halt on the Company's securities from the commencement of trading today, 13 March 2017.

 
Oilex gets ready to raise

2017-03-12 proactiveinvestors.com.au
Oilex (ASX:OEX) has been granted a trading halt by the ASX, pending details if a capital raising.

 
Oilex Ltd updates on strategy and Cambay

2016-09-29 proactiveinvestors.com.au
Oilex Ltd (ASX:OEX, LON:OEX) has told investors that it will significantly reduce its costs as it finalises the planning of a vertical well at its Cambay prospect in India. The company said the drilling of the proposed well remains subject to final cost estimates and obtaining the necessary funding. It did, however, add that it expects to start operations at some point in the first half of next year.

 
Oilex Ltd reaffirms commitment to Cambay Block project

2016-07-31 proactiveinvestors.com.au
Oilex Ltd (ASX:OEX) is an oil and gas exploration and production company focused on onshore unconventional opportunities around the Indian Ocean Rim.

 
Oilex Ltd planning new well at Cambay

2016-06-26 proactiveinvestors.com.au
Oilex Ltd (ASX:OEX) is an oil and gas exploration and production company focused on onshore unconventional opportunities around the Indian Ocean Rim.

 
Cancellation of Unlisted Options

2016-05-06 asx.com.au

 
Quarterly Report 31 March 2016

2016-04-29 asx.com.au

 
Oilex Appoints New MD - Jonathan Salomon

2016-03-18 londonstockexchange
The Board of Oilex Ltd (Oilex or the Company) announces the appointment of Jonathan (Joe) Salomon, currently an independent non-executive director, as the new Managing Director of the Company with immediate effect, following the resignation of Mr Ron Miller today as a director of the Company.

 
Appendix 3Z R Miller

2016-03-18 asx.com.au

 
Interim Report 31 December 2015

2016-03-14 asx.com.au

 
Expiry of Unlisted Options

2016-03-08 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...